Welcome to our dedicated page for Xbiotech SEC filings (Ticker: XBIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
XBiotech Inc. filings document governance, executive-compensation, shareholder-vote, and material-agreement disclosures for a British Columbia biopharmaceutical issuer. Recent Form 8-K reports cover board appointments, committee assignments, amendments to director information, executive employment arrangements, and annual meeting voting results.
The company’s proxy materials describe director elections, auditor ratification, advisory compensation votes, and equity incentive plan matters. These filings provide the formal record for XBiotech’s board structure, compensation oversight, shareholder voting mechanics, and related public-company governance actions.
XBiotech Inc. reported a net loss of $5.5 million for the three months ended March 31, 2026, an improvement from a $10.9 million loss a year earlier. Loss per share narrowed to $0.18 from $0.36 on a stable share count of 30,487,731.
Total operating expenses fell sharply as research and development dropped to $5.2 million from $11.6 million and general and administrative costs declined to $1.1 million from $1.9 million, largely reflecting lower bonuses and stock-based compensation linked to the former CEO.
The company ended the quarter with cash and cash equivalents of $115.5 million and total assets of $139.8 million, against shareholders’ equity of $135.0 million. Management states this cash should fund operations for at least 12 months, but it does not expect any revenue in 2026 and anticipates continued operating losses as it advances its True Human™ antibody pipeline.
XBiotech Inc. filed an amended annual report to add detailed Part III disclosures on directors, executive compensation, ownership and equity plans for the year ended December 31, 2025. As of March 13, 2026, 30,487,731 common shares were outstanding and non‑affiliate equity had a market value of about $77.1 million as of June 30, 2025.
Former CEO John Simard received 2025 total compensation of about $30.1 million, including salary, bonuses, option awards and severance, while the median employee earned $87,096, resulting in a CEO pay ratio of roughly 345:1. The filing also describes board committee structures, director pay, and the transition from the expired 2015 equity plan to a new 2025 plan covering up to 8.38 million shares.
XBiotech Inc. filed its annual report describing a pre-market biopharmaceutical business focused on True Human monoclonal antibodies, particularly IL‑1α therapies for cancer, arthritis and stroke, plus an infectious disease pipeline. The company previously received $750 million from selling Bermekimab and has returned $495 million to shareholders via buybacks and dividends.
XBiotech recorded a net loss for 2025 and spent about $47.4 million on research and development, reflecting ongoing heavy investment without product revenue. As of March 13, 2026, 30,487,731 common shares were outstanding and the company employed 85 full‑time staff while emphasizing extensive clinical, regulatory, financing and commercialization risks.
XBiotech Inc. shareholder W. Thorpe McKenzie filed an amended Schedule 13G reporting beneficial ownership of 3,006,259 common shares, representing 9.76% of XBiotech’s outstanding common shares as of December 31, 2025. This figure includes 302,500 shares issuable upon exercise of stock options that are exercisable within 60 days of that date.
McKenzie has sole voting and dispositive power over 2,899,971 shares and shared voting and dispositive power over 106,288 shares, which are held by related parties including the McKenzie Foundation, his spouse, and a trust for his stepchildren. He disclaims beneficial ownership of those related-party shares except to the extent of his pecuniary interest. The ownership percentage is based on 30,487,731 shares outstanding as of December 31, 2025 plus the option shares.
XBiotech Inc. insider ownership disclosure: Chairman of the Board John Simard reports beneficial ownership of 5,719,775 common shares of XBiotech Inc. as of December 31, 2025, representing 17.7% of the company’s common shares. This includes 3,823,166 shares held directly and 1,896,609 additional shares issuable upon exercise of stock options that are immediately exercisable within 60 days of December 31, 2025.
The 17.7% figure is based on 30,487,731 XBiotech common shares outstanding as of December 31, 2025, plus the 1,896,609 option shares attributed to Simard. He reports sole voting and dispositive power over all 5,719,775 shares, with no shared voting or dispositive authority and no group arrangements disclosed.
XBiotech Inc. reported Q3 2025 results, posting a net loss of $6.0 million as operating expenses fell with no active clinical trials. Cash and cash equivalents were $147.4 million at September 30, 2025, supporting ongoing R&D and facility plans.
Research and development expense was $5.1 million in Q3 (down from $7.1 million), mainly from lower clinical and manufacturing activity. General and administrative expense was $1.0 million. Other income reflected $1.4 million of interest income and a $1.2 million foreign exchange loss. For the nine months, net loss was $18.6 million.
The company repaid in full a $10 million related-party convertible loan on January 31, 2025, extinguishing conversion rights. On October 2, 2025, XBiotech entered a new executive employment agreement with its CEO, providing a $1,250,000 base salary, eligibility for a $4,530,442 base bonus, and severance equal to three years of base salary and base bonus upon certain separations. Shares outstanding were 30,487,731 as of November 12, 2025.
XBiotech Inc. (XBIT) reported a Form 4 for director Craig Rademaker. On October 1, 2025, he received a nonstatutory stock option grant for 92,104 options with an exercise price of $2.64 per share under the company’s 2025 Equity Incentive Plan. The options relate to common stock and were acquired at no cost.
The options vest in two equal portions at four months and ten months from the grant date and carry a 10-year term expiring on October 1, 2035. Following the transaction, 92,104 derivative securities are beneficially owned directly.
XBiotech (XBIT) disclosed that director David Soffer reported a grant of 51,000 nonstatutory stock options at an exercise price of $2.64 per share. The award was granted on October 1, 2025 under the company’s 2025 Equity Incentive Plan. According to the filing, the options vest in two equal portions at four months and ten months from the grant date and carry a ten-year term, expiring on October 1, 2035. Following the grant, 51,000 derivative securities are beneficially owned, held directly.
XBiotech (XBIT) reported a director equity grant. On October 1, 2025, the reporting person received 79,115 nonstatutory stock options to purchase common stock at an exercise price of $2.64, equal to the closing sale price on the grant date. The options vest in two equal portions at four months and ten months from the grant date and carry a 10-year expiration. The filing lists the holder’s relationship as Director and shows direct (D) ownership.
XBiotech Inc. filed a Form 4 reporting a director stock option grant. On October 1, 2025, the reporting person received 56,000 nonstatutory options with a per‑share exercise price of $2.64 under the company’s 2025 Equity Incentive Plan.
The options vest in two equal portions at four months and ten months from the grant date and expire on October 1, 2035. Following the transaction, 56,000 derivative securities were beneficially owned directly.